EyePoint Pharmaceuticals (EYPT) Competitors

EyePoint Pharmaceuticals (NASDAQ:EYPT) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Does the MarketBeat Community believe in EYPT or TRNS?

EyePoint Pharmaceuticals received 254 more outperform votes than Transcat when rated by MarketBeat users. Likewise, 70.20% of users gave EyePoint Pharmaceuticals an outperform vote while only 66.88% of users gave Transcat an outperform vote.

Company	Underperform	Outperform
EyePoint Pharmaceuticals	Outperform Votes 464 70.20%	Underperform Votes 197 29.80%
Transcat	Outperform Votes 210 66.88%	Underperform Votes 104 33.12%

Which has more risk and volatility, EYPT or TRNS?

EyePoint Pharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Which has higher earnings and valuation, EYPT or TRNS?

Transcat has higher revenue and earnings than EyePoint Pharmaceuticals. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EyePoint Pharmaceuticals	$45.71M	11.97	-$70.79M	-$2.00	-4.01
Transcat	$270.61M	3.72	$13.65M	$1.98	55.30

Do institutionals and insiders hold more shares of EYPT or TRNS?

99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media refer more to EYPT or TRNS?

In the previous week, EyePoint Pharmaceuticals and EyePoint Pharmaceuticals both had 7 articles in the media. EyePoint Pharmaceuticals' average media sentiment score of 0.54 beat Transcat's score of 0.17 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EyePoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer EYPT or TRNS?

EyePoint Pharmaceuticals presently has a consensus target price of $25.71, indicating a potential upside of 220.63%. Transcat has a consensus target price of $130.25, indicating a potential upside of 18.95%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EyePoint Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Transcat	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is EYPT or TRNS more profitable?

Transcat has a net margin of 6.63% compared to EyePoint Pharmaceuticals' net margin of -226.57%. Transcat's return on equity of 7.36% beat EyePoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EyePoint Pharmaceuticals	-226.57%	-43.01%	-31.63%
Transcat	6.63%	7.36%	5.90%

Summary

EyePoint Pharmaceuticals beats Transcat on 10 of the 17 factors compared between the two stocks.